AbbVie and Genmab are touting a much-anticipated first-line win for | Epkinly plus R-CHOP cut the risk of progression or death by 51% compared with R-CHOP alone in newly diagnosed DLBCL, setting up a ...

The trial met its primary end point of progression-free survival in patients with an International Prognostic Index (IPI) ...

The regimen achieved a statistically significant improvement in progression-free survival compared to R-CHOP alone.

AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large ...

Why do outcomes differ even when patients receive the same treatment?Even when patients are diagnosed with the same condition ...

Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The FDA rejected a supplemental Biologics License Application (sBLA) for glofitamab-gxbm (Columvi, Genentech) in combination with gemcitabine and oxaliplatin for the second-line treatment of relapsed ...

Diffuse large B-cell lymphoma (DLBCL) is a type of cancer that affects white blood cells called lymphocytes. There are two main types of lymphocytes: B-cell lymphocytes (B cells) and T-cell ...

Overexpression of MYC and BCL2 in DLBCL is linked to increased CCL2 and CCR2, promoting M2 macrophage polarization and aggressiveness. Elevated CCL2 and CCR2 expression correlates with poor ...

Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps The global study enrolled 483 patients with R/R DLBCL with at least ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...